Lawyers for the state of West Virginia are concluding the first week of a trial against three major opioid makers.
FILE - Dr. Rahul Gupta, the director of the White House Office of National Drug Control Policy, is shown at the White House, Thursday, Nov. 18, 2021, in Washington. Gupta was one of the first witnesses whose video deposition was played at a bench trial Tuesday, April 5, 2022, in which several pharmaceutical manufacturers are accused in a lawsuit of contributing to the crisis.
Much of the early testimony on Friday focused on materials produced by Cephalon Inc., a company bought by Teva, to sell fentanyl-based medications Actiq and Fentora.Perri described a “paradigm shift” from the late 1990s to early 2000s in which the companies transitioned from marketing opioids as drugs designed for terminal cancer patients to drugs designed to treat long-term pain.
One 2010 training manual used by sales representatives marketing the morphine drug Kadian repeatedly minimized the risk of addiction among users. Allergan owns the rights to Kadian.“Despite the continued unscientific beliefs of some clinicians, there is no evidence that simply taking opioids for a period of time will cause substance abuse or addiction," the document reads.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
John Cranley, Nan Whaley unveil plans for statewide summer school, lower drug costsDemocratic gubernatorial candidates John Cranley and Nan Whaley this week have unveiled their plans about what, if elected, they would do about summer school and prescription drug prices, respectively.
Read more »
Medicare Will Only Cover New Alzheimer’s Drug in TrialsFederal officials have made their final decision: Medicare will only pay for patients to get the new Alzheimer's drug aducanumab (Aduhelm) if the patients are participating in clinical trials.
Read more »
Medicare Weighs Premium Cut After Limiting Alzheimer's DrugMedicare said Thursday it's considering a cut in enrollee premiums after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer's drug projected to drive up program costs.
Read more »
Medicare limits coverage of controversial Alzheimer's drug to those in clinical trialsMedicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.
Read more »
Medicare Considers Cutting Premiums After Limiting Alzheimer’s Drug CoverageMedicare said Thursday it’s considering a cut in enrollee premiums after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs.
Read more »
Medicare limits payments for new Alzheimer’s drug to clinical trialsThe federal government affirmed its plan to limit coverage for a costly new medication for Alzheimer’s disease, restricting it to Medicare patients enrolled in clinical trials.
Read more »